Product Description: Cetuximab (PBS) is a human IgG1 monoclonal antibody that can inhibit EGFR. The SPR method measured the Kd value of Cetuximab for EGFR to be 0.201 nM; Cetuximab has a highly effective anti-tumor effect[1].
Applications: Cancer-Kinase/protease
Formula: N/A
References: [1]Goldstein, et al. Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model. Clinical cancer research: an official journal of the American Association for Cancer Research 1.11 (1995): 1311-1318./[2]Gustafsson H, et al. EPR Oximetry of Cetuximab-Treated Head-and-Neck Tumours in a Mouse Model. Cell Biochem Biophys. 2017 Jul 29./[3]Huang SM, et al. Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck. Cancer Res. 1999 Apr 15;59(8):1935-40.
Molecular Weight: N/A
Compound Purity: 99.27
Research Area: Cancer
Target: EGFR;Radionuclide-Drug Conjugates (RDCs)
English
Deutsch
